
STUDY: Gencor’s Levagen®+ Demonstrates Significant Support to Ease Menstrual Discomfort
Gencor has announced the publication of its recent human clinical study investigating its palmitoylethanolamide (PEA) ingredient, Levagen®+, to be a safe, innovative, and effective supplement to ease acute menstrual discomfort. Menstrual pain, or primary dysmenorrhea (menstrual pain without any underlying pathology), is the most common gynecological condition among women of reproductive age. It is estimated to be the leading cause of chronic pelvic pain globally (World Health Organization). The prevalence rate ranges from 45 to 95% and is linked to restrictions in daily activities, work and school absenteeism, and personal distress. While the primary mechanisms of dysmenorrhea are not fully understood, the main cause of the painful symptoms is attributed to the overproduction of uterine prostaglandins, particularly prostaglandin F2-α (PGF2α) and prostaglandin E2 (PGE2), which peak during the early days of menstruation. Besides their regulatory effects on inflammation, pain, and body temperature, prostaglandin production is also thought to contribute to secondary symptoms of menstrual pain, such as diarrhea, nausea, and vomiting. Moreover, women experiencing dysmenorrhea may show elevated levels of pro-inflammatory mediators and an increased body temperature. Preclinical research suggests that PEA’s primary mechanism of action is to provide relief from occasional discomfort and support a balanced inflammatory response, which may